On Wednesday, H.C. Wainwright increased its stock price target for Scholar Rock (NASDAQ: SRRK) shares, setting it at $40, up from the previous target of $35. The firm has also reaffirmed its Buy rating on the stock. This adjustment comes after Scholar Rock revealed promising results from its SAPPHIRE trial, which evaluated the effectiveness of apitegromab in non-ambulatory patients with Types 2 and 3 spinal muscular atrophy (SMA), who were also receiving SMN-targeted therapies.
The SAPPHIRE trial data, which was announced earlier, showed a significant 1.8-point improvement in the Hammersmith Functional Motor Scale Expanded (HFMSE) score for patients treated with apitegromab compared to those given a placebo. This improvement was statistically significant with a p-value of 0.0192.
The trial also demonstrated consistent and clinically meaningful benefits across a broad age range, from 2 to 21 years. Notably, 30% of the patients treated with apitegromab experienced an improvement of more than 3 points in the HFMSE score.
These advancements were observed in addition to the standard care that SMA patients normally receive, marking a considerable stride forward in the treatment of the disease. Furthermore, the safety profile of apitegromab was favorable and in line with the data collected over 48 months from the Phase 2 TOPAZ trial.
Looking ahead, Scholar Rock is preparing to submit a U.S. Biologics License Application (BLA) and a European Union marketing authorization application (MAA) in the first quarter of 2025. The firm's analyst expressed optimism about the stock's potential to outperform market expectations for apitegromab.
This sentiment is further strengthened by the anticipation of updates from Scholar Rock's other programs, including its obesity program (SRK-439) and the oncology asset (linavonkibart).
In light of the upcoming BLA submission and the potential market launch of apitegromab, H.C. Wainwright has updated its operating expense assumptions for Scholar Rock. The firm's continued confidence in the company's prospects is reflected in the revised price target and the maintained Buy rating.
In other recent news, biopharmaceutical company Scholar Rock reported positive results from its Phase 3 SAPPHIRE study for the drug apitegromab, a potential treatment for spinal muscular atrophy (SMA). The study met its primary endpoints, resulting in a significant improvement in motor function. The company has a robust financial position, with a cash balance of approximately $463 million following a $345 million follow-on offering.
Scholar Rock is preparing to submit regulatory applications in Q1 2025, with a U.S. commercial launch of apitegromab planned for Q4 2025. The company is also developing SRK-439 and conducting the EMBRAZE Phase 2 study, both aimed at obesity management.
Analysts suggest that apitegromab has the potential to generate over $1 billion in revenue. These developments reflect the company's recent focus on addressing unmet needs in SMA treatment and obesity management.
InvestingPro Insights
Scholar Rock's recent positive trial results and H.C. Wainwright's increased price target are reflected in the company's strong market performance. According to InvestingPro data, Scholar Rock has seen a remarkable 174.56% price return over the last three months and a 169.84% return over the past year. This aligns with the InvestingPro Tip highlighting the stock's "strong return over the last three months."
Despite these gains, investors should note that Scholar Rock is not currently profitable, with a negative P/E ratio of -12.02 for the last twelve months as of Q2 2024. This is consistent with the InvestingPro Tip stating that "analysts do not anticipate the company will be profitable this year."
The company's market capitalization stands at $2.45 billion, reflecting investor optimism about its potential. However, it's worth noting that Scholar Rock "operates with a moderate level of debt" and "suffers from weak gross profit margins," according to InvestingPro Tips. These factors may be important considerations as the company moves towards potential product launches and increased operational expenses.
For investors seeking a more comprehensive analysis, InvestingPro offers 14 additional tips for Scholar Rock, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.